# Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity

> **NCT04788511** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 529 (actual)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo (semaglutide)

## Key facts

- **NCT ID:** NCT04788511
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-16
- **Primary completion:** 2023-04-18
- **Final completion:** 2023-04-18
- **Target enrollment:** 529 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04788511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04788511, "Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04788511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*